Verrica Pharmaceuticals Inc. (VRCA)
Stock Price:
$7.89 USD
-0.21 (-2.59%)
Updated Oct 27, 2020 12:38 PM EDT - Market open
Key Info
| Market Cap |
203.68M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-32.96M |
| Shares Out |
25.81M |
| EPS (ttm) |
-1.32 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$7.89 |
| Previous Close |
$8.10 |
| Change ($) |
-0.21 |
| Change (%) |
-2.59% |
| Day's Open |
8.13 |
| Day's Range |
7.89 - 8.32 |
| Day's Volume |
20,783 |
| 52-Week Range |
6.02 - 18.67 |
More Stats
| Market Cap |
203.68M |
| Enterprise Value |
158.90M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.81M |
| Float |
12.62M |
| EPS (basic) |
-1.31 |
| EPS (diluted) |
-1.32 |
| FCF / Share |
-1.34 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.55M |
| Short Ratio |
17.06 |
| Short % of Float |
20.22% |
| Beta |
2.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.58 |
| Revenue |
n/a |
| Operating Income |
-33.04M |
| Net Income |
-32.96M |
| Free Cash Flow |
-33.44M |
| Net Cash |
44.78M |
| Net Cash / Share |
1.73 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.52% |
| ROE |
-52.60% |
| ROIC |
-57.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$19.00*
(140.81% upside)
Low
15.0
Current: $7.89
High
25.0
Target: 19.00
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -30.08 | -21.88 | -4.46 | -1.91 |
| Net Income | -28.21 | -20.65 | -4.46 | -1.91 |
| Shares Outstanding | 24.90 | 14.66 | 2.85 | 6.32 |
| Earnings Per Share | -1.13 | -1.41 | -1.56 | -0.30 |
| Operating Cash Flow | -27.41 | -17.87 | -4.58 | -1.61 |
| Capital Expenditures | -0.68 | -0.77 | - | - |
| Free Cash Flow | -28.09 | -18.65 | -4.58 | -1.61 |
| Cash & Equivalents | 62.02 | 90.31 | 8.66 | 0.53 |
| Total Debt | 0.19 | - | - | - |
| Net Cash / Debt | 61.83 | 90.31 | 8.66 | 0.53 |
| Assets | 68.42 | 91.91 | 9.08 | 0.54 |
| Liabilities | 3.41 | 2.48 | 0.62 | 0.42 |
| Book Value | 65.02 | 89.43 | -7.04 | -2.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Verrica Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
17 |
| CEO |
Ted White |
Stock Information
| Ticker Symbol |
VRCA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VRCA |
| IPO Date |
June 15, 2018 |
Description
Verrica Pharmaceuticals, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.